7.0 References


25. Chen JJ, Berchou RC. Rasagiline, a selective, second-generation, irreversible inhibitor of monoamine oxidase type B, is effective in patients older and younger than 65 years of age with early-to-advanced Parkinson’s disease (PD), Pharmacotherapy. 2004; 24: 1449. Abstract.


56. Irene A Malaty, Hubert H Fernandez; Review: Role of rasagiline in treating Parkinson’s disease: Effect on disease progression, Therapeutics and Clinical Risk Management, 2009:5 413–419.


75. M. Finberg, John; Takeshima, Takao; Johnston, Jane M.; Commissiong, John W. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor, Neuropharmacology and Neurotoxicology, Neuroreport: 9 March 1998:9(4), 703-707.


86. Nicola Vanacore, What Is the Clinical Significance of the Findings from the Delayed-Start Trial of Rasagiline in Parkinson’s Disease? Neuroepidemiology 2010;35:213.


102. Rascol O, Brooks DJ, Melamed E, et al, for the LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily,


135. Williams RL, Adams W, Chen ML, Hare D, Hussain A, Lesko L. Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? Eur J Drug Metab Pharmacokinet. 2000a; 25:7-12.


137. Wilson, Ronald E et al, Rasagiline: Time to Onset of Antiparkinson Effect is Similar When Used as a Monotherapy or Adjunct Treatment, Neurologist: November 2011:17(6), 318–324.


